Shots:

• The P-II 218 study involves assessing Lenvima (14mg- qd) + everolimus (5mg- qd) vs Lenvima (18mg- qd) + everolimus (5mg qd) in patients with clear-cell RCC- following treatment with an anti-angiogenic therapy- with prior anti-PD-1/PD-L1 therapy permitted
• In the primary analysis- @24wks. ORR (32.1% vs 34.8%) i.e. lower dose did not meet the threshold for non-inferiority; Grade 2/ any ≥ Grade 3 TEAEs (82.8% vs 79.6%); discontinuation (32.4% vs 26.8%); dose interruption (74.6% vs 83.3%); dose reductions (67.6% vs 69.6%)
• Overall ORR (34.6% vs 40.6%); mPFS (11.1 vs 14.7mos.); m-OS (27.0 vs NE). Results were presented at IKCS 2020

 ­ Ref: PRNewswire | Image: Welwyn Hatfield Times